AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MOBI

Leavitt Chase C. purchased $21K of MOBI

Leavitt Chase C. (SEE REMARKS) purchased 2,000 shares of Mobia Medical, Inc. (MOBI) at $10.30 on 2026-09-11.

Original reporting
SEC EDGAR · Leavitt Chase C.
Published Sep 15, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MOBI
Neutral
medium confidence
Mentioned
$MOBI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBINeutralLow
01

Why it matters

The purchase adds 2,000 shares to the officer's holdings, a modest increase that may be viewed positively by some investors but is unlikely to affect price.

02

Market read

New insider purchase provides fresh data for traders monitoring Mobia Medical, but the small size limits actionable impact.

03

What to watch

Potential upcoming clinical milestones or financing events not disclosed in the filing.

Relevance 4/10Novelty 6/10Timing: filed Sep 15 2026

Background

Form 4 filings disclose insider trades; they are primary sources for new insider activity.

Company-level read

Ticker impact

$MOBINeutralMedium confidence
Context

Officer Leavitt Chase C. purchased 2,000 shares of Mobia Medical for $20,600, increasing holdings to 5,000 shares.

Expected impact

Minimal price movement expected; may slightly support short-term bullish sentiment.

Evidence & confidence

The transaction is under $1M and represents a modest stake increase for an officer, unlikely to move the stock materially.

Market effects

Sector

No significant sector impact; insider activity is company‑specific.

Regional

Limited to U.S. investors tracking Mobia Medical.

Global

Negligible

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Officer
    Leavitt Chase C.

    Insider who executed the purchase.

  • Company
    Mobia Medical, Inc.

    Biotech firm whose stock is affected.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MOBI insider trading history →

Related articles

$MOBIMed

What Mobia Medical (MOBI) Said on Its Q3 Earnings Call

Mobia Medical (MOBI) reported Q3 earnings with a net loss of $17.3M ($0.52 per share), improved from last year. Gross margin rose to 83.2%. Operating expenses increased to $31.5M due to higher personnel costs. The company cited positive impacts from revised stroke recovery guidelines and expects to publish clinical evidence in 2027.

finance.yahoo.com
$MOBIHigh

Mobia Medical Reports Third Quarter 2026 Financial Results

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Third Quarter 2026 Financial Results Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke

SEC EDGAR 8-K
$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

investing.com